Correlation Engine 2.0
Clear Search sequence regions

  • argon (1)
  • bone (2)
  • bone neoplasms (1)
  • extremities (3)
  • giant cell tumor (6)
  • humans (1)
  • hydrogen (2)
  • limbs (1)
  • patients (2)
  • phenol (1)
  • sas (1)
  • Sizes of these terms reflect their relevance to your search.

    Giant cell tumour (GCT) represents 5% of all primitive bone tumours. Standard surgical treatment of GCT includes intralesional excision or segmental resection. Curettage has a higher recurrence rate (10-25% in stage 2 or 3 but does preserve adjacent joint function. The use of local adjuvants such as phenol, alcohol, H2O2, Argon or cement may decrease recurrence rate, yet which local adjuvant works best is still, to this day, controversial. A series of 109 patients with GCT of the extremity, surgical treated in a single Institution from 2016 to 2018, were analysed in a retrospective study. The purpose of our study was to report the incidence of recurrence rate in patients with GCT of limbs treated in a single institution with different local adjuvants. The results of the present study suggests that curettage in association to cryoablation seems to reduce the recurrence rate compared to "classic" local adjuvants. Copyright 2020 Biolife Sas.


    S Colangeli, A Del Chiaro, L Andreani, A D'Arienzo, P Parchi, R Capanna. Giant cell tumor of extremities, surgical treatment and local adjuvants: which is the most effective? Journal of biological regulators and homeostatic agents. 2020 Sep-Oct;34(5 Suppl. 1):57-62. IORS Special Issue on Orthopedics

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 33739006

    View Full Text